Blocknomi
Key Highlights Shares of Q32 Bio climbed approximately 60% following encouraging 36-week findings from the SIGNAL-AA Phase 2a study evaluating bempikibart for alopecia areata The study successfully achieved its primary…
Related articles
-
UK crypto investors sue Binance, Changpeng Zhao for $200M
Cointelegraph Published 01.07.2026 02:30
-
Spot Bitcoin ETFs Extend Losing Streak With $231M Outflow as Ether Funds Lose $30M
Blocknomi Published 30.06.2026 09:58
-
Ripple's RLUSD Rapidly Shrinks as New Major Stablecoin Emerges
U.Today Published 30.06.2026 19:57
-
Even at 0% Bitcoin Returns, MicroStrategy Could Last 40–50 Years, Says Michael Saylor
BlockchainReporter Published 10.07.2026 17:00
-
Sell Signal Flashes: What Strategy’s Massive $216M Sale Means for Bitcoin’s Price
CryptoPotato Published 06.07.2026 14:00
-
From Tokenized Stocks to CASHCAT – Why Robinhood Chain Is Dominating Crypto Conversations
CryptoPotato Published 10.07.2026 09:50
-
TeraWulf signs 20-year data center lease with Anthropic expected to generate $19 billion in revenue
The Block Published 06.07.2026 14:02
-
Bitcoin ETF Inflows Return As BlackRock Helps Rebuild Institutional Demand
NewsBTC Published 09.07.2026 11:55